Original Literature | Model OverView |
---|---|
Publication
Title
Functions of anaphylatoxin C5a in rat liver: direct and indirect actions onnonparenchymal and parenchymal cells.
Affiliation
Institut fur Biochemie und Molekulare Zellbiologie, Georg-August-UniversitatGottingen, Humboldtallee 23, D-37073 Gottingen, Germany. hschief@gwdg.de
Abstract
Growing evidence obtained in recent years indicates that anaphylatoxin C5areceptors (C5aR) are not restricted to myeloid cells but are also expressed onnonmyeloid cells in different tissues such as brain, lung, skin and liver. Incontrast to its well-defined systemic functions, the actions of anaphylatoxinsin these organs are poorly characterized. The liver can be a primary targetorgan for the C5a anaphylatoxin since the liver is directly connected to thegut, via the mesenteric veins and portal vein which is a main source ofcomplement activating lipopolysaccharides (LPS). In the normal rat liver, theC5aR is only expressed by nonparenchymal cells, i.e. strongly by Kupffer cells(KC) and hepatic stellate cells (HSC) and weakly by sinusoidal endothelial cells(SEC), but not expressed by the parenchymal hepatocytes (HC). Accordingly,direct effects of C5a were only found in the C5aR-expressing KC and HSC: C5ainduced the release of prostanoids from KC and HSC and enhanced theLPS-dependent release of interleukin-6 from KC. These soluble mediatorsindirectly influenced effector functions of the C5aR-free HC. C5a enhanced theglycogen phosphorylase activity and thus the glucose output from HC indirectlyvia prostanoids released from KC and HSC. Glucose can serve as an energysubstrate as well as an electron donor for the synthesis of reactive oxygenintermediates by KC. Moreover, C5a also enhanced transcription of the gene forthe type-2 acute phase protein alpha 2-macroglobulin in HC indirectly byincreasing LPS-dependent IL-6 release from KC. Under pathological conditions,C5aR was found to be upregulated in various organs including the liver.Simulation of inflammatory conditions by treatment of rats with IL-6, a maininflammatory mediator in the liver, caused a de novo expression of functionalC5aR in HC. In livers of IL-6-treated rats, C5a initiated glucose output from HCand perhaps other HC-specific defense reactions directly without theintervention of soluble mediators from nonparenchymal cells.
PMID
11367531
|
Entity
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
PGD2
--
e11
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m11
0
infinite
0
--
--
e12
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m12
0
infinite
0
--
C5a{Gly}
--
e13
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m13
0
infinite
0
--
C5aR
--
e14
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m14
0
infinite
0
--
C5a{Gly}:C5aR
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m15
0
infinite
0
--
LPS
--
e16
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m16
0
infinite
0
--
TLR receptor
--
e17
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m17
0
infinite
0
--
LPS:TLR
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m18
0
infinite
0
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
csml-variable:Double
m20
0
infinite
0
--
csml-variable:Double
m21
0
infinite
0
--
IL-6
--
e22
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m22
0
infinite
0
--
Il-1beta
--
e23
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m23
0
infinite
0
--
TNf-alpha
--
e24
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m24
0
infinite
0
--
Type 2
--
e25
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m25
0
infinite
0
--
Type 1
--
e26
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m26
0
infinite
0
--
Type 1
--
e27
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m27
0
infinite
0
--
Type2
--
e28
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m28
0
infinite
0
--
TNF-alpha receptor
--
e29
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
TNF-alpha:receptor
--
e30
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m30
0
infinite
0
--
IL-1beta receptor
--
e31
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m31
0
infinite
0
--
IL-1 beta:receptor
--
e32
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m32
0
infinite
0
--
IL-6 receptor
--
e33
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m33
0
infinite
0
--
IL-6:receptor
--
e34
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m34
0
infinite
0
--
alpha2 macroglobulin
--
e35
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m35
0
infinite
0
--
csml-variable:Double
m36
0
infinite
0
--
Glycogen phosphorylase
--
e37
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m37
0
infinite
0
--
Glycogen phosphorylase{active}
--
e38
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m38
0
infinite
0
--
antitrypsin
--
e39
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
antichymotrypsin
--
e40
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m40
0
infinite
0
--
albumin
--
e41
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m41
0
infinite
0
--
transferrin
--
e42
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m42
0
infinite
0
--
antitrypsin
--
e43
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m43
0
infinite
0
--
antichymotrypsin
--
e44
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m44
0
infinite
0
--
albumin
--
e45
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m45
0
infinite
0
--
transferrin
--
e46
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m46
0
infinite
0
--
C5
--
e47
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m47
0
infinite
0
--
PGE2
--
e48
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m48
0
infinite
0
--
C3a
--
e49
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m49
0
infinite
0
--
Phospholipids
--
e5
cso30:c:SmallMolecule
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
arachidonic acid
--
e6
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
Calcium
--
e63
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m63
0
infinite
0
--
IP3
--
e64
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m64
0
infinite
0
--
zymosan
--
e65
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m65
0
infinite
0
--
csml-variable:Double
m66
0
infinite
0
--
--
e67
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m67
0
infinite
0
--
PGF2
--
e68
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m68
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
m5*0.1
nodelay
--
0
PMID:11367531 Prostanoids are generated enzymatically from arachidonic acid released from phospholipids in the cellular membranes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c27 : 1
m19*m18*m15*0.1
nodelay
--
0
PMID:11367531, 3116090, 2208809 In isolated KC, C5a alone did not induce IL-6 synthesis, but synergistically enhanced the LPS-dependent IL-6 synthesis both on the mRNA and on the protein level, again demonstrating the different roles of distinct inflammatory mediators in the regulation of liver-specific effector functions. In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c30 : 1
m15*0.1
nodelay
--
0
PMID: 11367531 In contrast to its role in IL-6 synthesis, C5a induced the expression of both IL-1b- and TNFa-mRNA but not of IL-1b- and TNFa-protein.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c31 : 1
m15*0.1
nodelay
--
0
PMID: 11367531 In contrast to its role in IL-6 synthesis, C5a induced the expression of both IL-1b- and TNFa-mRNA but not of IL-1b- and TNFa-protein.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c36 : 1
stoichiometry:c38 : 1
stoichiometry:c37 : 1
m20*m15*0.1
nodelay
--
0
PMID: 11367531,3116090, 2208809 In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c39 : 1
stoichiometry:c35 : 1
m15*m19*0.1
nodelay
--
0
PMID: 11367531,3116090, 2208809 In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m15*m21*0.1
nodelay
--
0
PMID: 11367531,3116090, 2208809 In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c51 : 1
stoichiometry:c57 : 1
stoichiometry:c53 : 1
m26*m30*0.1
nodelay
--
0
PMID: 11367531, 10422197 While type-1 acute phase proteins are mainly induced by IL-1b and TNFa, type-2 acute phase proteins are predominantly induced by IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c45 : 1
stoichiometry:c46 : 1
m20*m15*m18*0.1
nodelay
--
0
PMID: 11367531,3116090, 2208809 In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c146 : 1
stoichiometry:c49 : 1
m15*m18*m21*0.1
nodelay
--
0
PMID: 11367531,3116090, 2208809 In monocytes and macrophages of peripheral blood C5a has also been described to induce IL-6-, IL-1b- and TNFarelease either alone or in combination with other proinflammatory agents such as LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c61 : 1
stoichiometry:c52 : 1
m26*m32*0.1
nodelay
--
0
PMID: 11367531, 10422197 While type-1 acute phase proteins are mainly induced by IL-1b and TNFa, type-2 acute phase proteins are predominantly induced by IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c3 : 1
stoichiometry:c105 : 1
stoichiometry:c10 : 1
m6*m15*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC. After stimulation with rrC5a, KC not only released predominantly PGD2 and TXA2, but also PGF2¦Á and PGE2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c55 : 1
stoichiometry:c56 : 1
m24*m29*0.1
nodelay
--
0
PMID: 11367531 TNF-alpha binds its corresponding receptor
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c59 : 1
stoichiometry:c60 : 1
m23*m31*0.1
nodelay
--
0
PMID:11367531 IL-1beta binds its corresponding receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
m33*m22*0.1
nodelay
--
0
PMID: 11367531 IL-6 binds its respective receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c67 : 1
stoichiometry:c66 : 1
m25*m34*0.1
nodelay
--
0
PMID: 11367531, 10422197 While type-1 acute phase proteins are mainly induced by IL-1b and TNFa, type-2 acute phase proteins are predominantly induced by IL-6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c69 : 1
stoichiometry:c70 : 1
stoichiometry:c68 : 1
m18*m15*0.1
nodelay
--
0
PMID: 11367531 How- 2 ever, the conditioned media of KC, which had been treated with C5a and LPS, enhanced the expression of a -macroglobulin mRNA significantly more than 2 conditioned media of KC, which had been treated with LPS alone
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c72 : 1
m18*0.1
nodelay
--
0
PMID: 11367531 How- 2 ever, the conditioned media of KC, which had been treated with C5a and LPS, enhanced the expression of a -macroglobulin mRNA significantly more than 2 conditioned media of KC, which had been treated with LPS alone
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
m18*0.1
nodelay
--
0
PMID: 11367531, 7836770, 9464274 The intraperitoneal injection of lipopolysaccharide, a major trigger of inflammation, increased C5aR mRNA expression in various organs of mouse and ratincluding the liver.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c76 : 1
m34*0.1
nodelay
--
0
PMID: 11367531, 10799912 It could be shown that in vivo treatment of rats with IL-6 led to a time-dependent expression of C5aR mRNA with a maximum between 4 and 8 h and of C5aR protein 8?10 h after IL-6 treatment
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c79 : 1
stoichiometry:c78 : 1
m36*m34*0.1
nodelay
--
0
PMID: 11367531, 10799912 It could be shown that in vivo treatment of rats with IL-6 led to a time-dependent expression of C5aR mRNA with a maximum between 4 and 8 h and of C5aR protein 8?10 h after IL-6 treatment
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c83 : 1
stoichiometry:c80 : 1
stoichiometry:c82 : 1
m37*m34*m15*0.1
nodelay
--
0
PMID: 11367531, 7556629, 9742932 The de novo expressed receptors were functional, since in HC from IL-6-treated rats C5a directly activated glycogen phosphorylase; in contrast it acted indirectly on HC from control animals via prostanoids released from C5aR expressing KC or HSC.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c6 : 1
stoichiometry:c7 : 1
stoichiometry:c8 : 1
m13*m14*0.1
nodelay
--
0
PMID: 11367531, 9272704, 9464523 Receptors for C5a ?C5aRrCD88. have been cloned in various species including rat,man and mouse.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c92 : 1
stoichiometry:c88 : 1
m39*m15*0.1
nodelay
--
0
PMID: 11367531, 7541417, 7540650 This is supported by the findings that, in the C5aR expressing tumor cells, HepG2 C5a induced the acute phase proteins a -an- 1 titrypsin and a -antichymotrypsin and repressed the 1 negative acute phase proteins albumin and transferrin
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c93 : 1
stoichiometry:c89 : 1
m40*m15*0.1
nodelay
--
0
PMID: 11367531, 7541417, 7540650 This is supported by the findings that, in the C5aR expressing tumor cells, HepG2 C5a induced the acute phase proteins a -an- 1 titrypsin and a -antichymotrypsin and repressed the 1 negative acute phase proteins albumin and transferrin
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c86 : 1
stoichiometry:c94 : 1
stoichiometry:c91 : 1
m41*0.1
nodelay
--
0
PMID: 11367531, 7541417, 7540650 This is supported by the findings that, in the C5aR expressing tumor cells, HepG2 C5a induced the acute phase proteins a -an- 1 titrypsin and a -antichymotrypsin and repressed the 1 negative acute phase proteins albumin and transferrin
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c95 : 1
stoichiometry:c90 : 1
m42*0.1
nodelay
--
0
PMID: 11367531, 7541417, 7540650 This is supported by the findings that, in the C5aR expressing tumor cells, HepG2 C5a induced the acute phase proteins a -an- 1 titrypsin and a -antichymotrypsin and repressed the 1 negative acute phase proteins albumin and transferrin
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c96 : 1
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m47*m18*0.1
nodelay
--
0
PMID: 11367531 The anaphylatoxin C5a is generated by limited proteolysis from the N-terminus of the alpha-chain of the fifth component of complement, C5
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c115 : 1
stoichiometry:c120 : 1
m6*m49*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC.
p36
p36
cso30:i:ME_ChangeInMaterialConcentration
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c103 : 1
m15*0.1
nodelay
--
0
PMID: 11367531 The C5aR is a G-protein-coupled receptor with seven transmembrane segments (seven TMS receptors) belonging to the rhodopsin family and acting via an increase in intracellular inositol-1,4,5-triphosphate (IP3) and intracellular Ca2+.
p36
p37
cso30:i:ME_ChangeInMaterialConcentration
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c102 : 1
stoichiometry:c104 : 1
m15*0.1
nodelay
--
0
PMID: 11367531 The C5aR is a G-protein-coupled receptor with seven transmembrane segments (seven TMS receptors) belonging to the rhodopsin family and acting via an increase in intracellular inositol-1,4,5-triphosphate (IP3) and intracellular Ca2+.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c112 : 1
stoichiometry:c116 : 1
stoichiometry:c119 : 1
m6*m49*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c109 : 1
stoichiometry:c100 : 1
stoichiometry:c110 : 1
m6*m15*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC. After stimulation with rrC5a, KC not only released predominantly PGD2 and TXA2, but also PGF2¦Á and PGE2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c9 : 1
stoichiometry:c114 : 1
stoichiometry:c121 : 1
m6*m49*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c106 : 1
stoichiometry:c108 : 1
m6*m15*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC. After stimulation with rrC5a, KC not only released predominantly PGD2 and TXA2, but also PGF2¦Á and PGE2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c5 : 1
stoichiometry:c107 : 1
stoichiometry:c99 : 1
m6*m15*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC. After stimulation with rrC5a, KC not only released predominantly PGD2 and TXA2, but also PGF2¦Á and PGE2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c117 : 1
stoichiometry:c118 : 1
m6*m49*0.1
nodelay
--
0
PMID: 11367531, 8244278, 7556629 Native human C3a [43] as well as rrC5a [44] rapidly induced prostanoid release from KC.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c122 : 1
stoichiometry:c126 : 1
stoichiometry:c133 : 1
m6*m65*0.1
nodelay
--
0
PMID: 11367531, 8281925 After the application of zymosan, prostanoid release was initiated as fast as after stimulation with rrC5a, but the maximum was only reached after 10?30 min [46 and 47].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c127 : 1
stoichiometry:c132 : 1
m6*m65*0.1
nodelay
--
0
PMID: 11367531, 8281925 After the application of zymosan, prostanoid release was initiated as fast as after stimulation with rrC5a, but the maximum was only reached after 10?30 min [46 and 47].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c124 : 1
stoichiometry:c128 : 1
stoichiometry:c131 : 1
m6*m65*0.1
nodelay
--
0
PMID: 11367531, 8281925 After the application of zymosan, prostanoid release was initiated as fast as after stimulation with rrC5a, but the maximum was only reached after 10?30 min [46 and 47].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c129 : 1
stoichiometry:c130 : 1
m6*m65*0.1
nodelay
--
0
PMID: 11367531, 8281925 After the application of zymosan, prostanoid release was initiated as fast as after stimulation with rrC5a, but the maximum was only reached after 10?30 min [46 and 47].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c138 : 1
stoichiometry:c142 : 1
m6*m18*0.1
nodelay
--
0
PMID: 11357531, 2390987 In contrast, prostanoid release induced by LPS was measurable only after 3?5 h [46 and 48].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c139 : 1
stoichiometry:c143 : 1
m6*m18*0.1
nodelay
--
0
PMID: 11357531, 2390987 In contrast, prostanoid release induced by LPS was measurable only after 3?5 h [46 and 48].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c136 : 1
stoichiometry:c140 : 1
stoichiometry:c144 : 1
m6*m18*0.1
nodelay
--
0
PMID: 11357531, 2390987 In contrast, prostanoid release induced by LPS was measurable only after 3?5 h [46 and 48].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c12 : 1
stoichiometry:c13 : 1
m16*m17*0.1
nodelay
--
0
PMID: 11367531 LPS binds its receptor TLR.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c141 : 1
stoichiometry:c145 : 1
m6*m18*0.1
nodelay
--
0
PMID: 11357531, 2390987 In contrast, prostanoid release induced by LPS was measurable only after 3?5 h [46 and 48].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c14 : 1
stoichiometry:c20 : 1
stoichiometry:c17 : 1
m19*m18*0.1
nodelay
--
0
PMID: 11367531, 2170121 LPS is known to induce the synthesis of these proinflammatory cytokines (IL-6, Il-1beta and TNF-alpha) in KC
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c21 : 1
stoichiometry:c18 : 1
m20*m18*0.1
nodelay
--
0
PMID: 11367531, 2170121 LPS is known to induce the synthesis of these proinflammatory cytokines (IL-6, Il-1beta and TNF-alpha) in KC
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c22 : 1
stoichiometry:c19 : 1
m21*m18*0.1
nodelay
--
0
PMID: 11367531, 2170121 LPS is known to induce the synthesis of these proinflammatory cytokines (IL-6, Il-1beta and TNF-alpha) in KC
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c25 : 1
stoichiometry:c23 : 1
m18*m15*0.1
nodelay
--
0
PMID:11367531 In isolated KC, C5a alone did not induce IL-6 synthesis, but synergistically enhanced the LPS-dependent IL-6 synthesis both on the mRNA and on the protein level, again demonstrating the different roles of distinct inflammatory mediators in the regulation of liver-specific effector functions.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--